Extensions of marketing authorisations: questions and answers

This page lists questions that marketing-authorisation holders (MAHs) may have on type-II-variation and extension applications. It provides an overview of the European Medicines Agency's position on issues that are typically addressed in discussions or meetings with MAHs in the post-authorisation phase. Revised topics are marked 'New' or 'Rev.' upon publication.

These questions and answers have been produced for guidance only and should be read in conjunction with the rules governing medicinal products in the European Union, volume 2, notice to applicants.

MAHs must in all cases comply with the requirements of Community legislation. Provisions that extend to Iceland, Liechtenstein and Norway by virtue of the European Economic Area agreement are outlined in the relevant sections of the text.

PDF versions of Q&As (the entire post-authorisation guidance)


How useful was this page?

Add your rating
6 ratings
11 ratings
7 ratings
10 ratings
5 ratings